セルジェンテック株式会社

Chiba, JP · 1 known investors

CellGenTech develops ex-vivo gene therapy products using gene-transduced human adipose cells (GMAC) to treat rare diseases such as familial LCAT deficiency, Fabry disease, and hemophilia. The Japanese biotech company works with academic and pharmaceutical partners on regenerative medicine products and also holds cell-preservation solution technology.

BiotechDeep TechHealthtech